These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36755044)

  • 21. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.
    Becq F
    Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small-molecule drugs for cystic fibrosis: Where are we now?
    Laselva O; Guerra L; Castellani S; Favia M; Di Gioia S; Conese M
    Pulm Pharmacol Ther; 2022 Feb; 72():102098. PubMed ID: 34793977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.
    O'Reilly R; Elphick HE
    Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the diagnosis and treatment of cystic fibrosis.
    Martiniano SL; Hoppe JE; Sagel SD; Zemanick ET
    Adv Pediatr; 2014 Aug; 61(1):225-43. PubMed ID: 25037130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein].
    Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A
    Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Update on CFTR Modulators as New Therapies for Cystic Fibrosis.
    King JA; Nichols AL; Bentley S; Carr SB; Davies JC
    Paediatr Drugs; 2022 Jul; 24(4):321-333. PubMed ID: 35570261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Entering the era of highly effective modulator therapies.
    Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetics of Cystic Fibrosis: Clinical Implications.
    Egan ME
    Clin Chest Med; 2016 Mar; 37(1):9-16. PubMed ID: 26857764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic therapies in cystic fibrosis.
    Taylor-Cousar JL; Boyd AC; Alton EWFW; Polineni D
    Curr Opin Pulm Med; 2023 Nov; 29(6):615-620. PubMed ID: 37700667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
    Fanen P; Wohlhuter-Haddad A; Hinzpeter A
    Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation-specific therapies and drug repositioning in cystic fibrosis.
    Villella VR; Tosco A; Esposito S; Bona G; Raia V; Maiuri L
    Minerva Pediatr; 2019 Jun; 71(3):287-296. PubMed ID: 30761820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
    Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
    Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.
    Allaire NE; Griesenbach U; Kerem B; Lueck JD; Stanleigh N; Oren YS
    J Cyst Fibros; 2023 Mar; 22 Suppl 1(Suppl 1):S39-S44. PubMed ID: 36658041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis.
    Schneider-Futschik EK
    Gene Ther; 2019 Sep; 26(9):354-362. PubMed ID: 31300729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
    Edmondson C; Course CW; Doull I
    Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.